Effect of Buprenorphine and Bupropion in the reduction of hashish craving

Effect of Buprenorphine and Bupropion in the reduction of cannabis craving

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016040525160N3

Enrollment

Registered

2016-07-30

Start date

2016-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cannabis Dependency. Mental and behavioural disorders due to use of cannabinoids

Interventions

Intervention 1: Intervention 1: Buprenorphine 4 mg per day for 2 weeks. Intervention 2: Intervention 2: Bupropion 150 mg per day for 2 weeks.

Treatment - Drugs

Intervention 1: Buprenorphine 4 mg per day for 2 weeks

Intervention 2: Bupropion 150 mg per day for 2 weeks

Eligibility

Sex/Gender

Male

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 18 to 50; They are free to participate in the study, patient's major substance use be cannabis Exclusion criteria: Patients unwilling to participate at beginning or during the study, use of another substance except cannabis as of the main substance.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Craving. Timepoint: daily for 2 weeks. Method of measurement: questionnaire and interview.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJamshid Ahmadi M.D.

Shiraz University of Medical Science

jamshid_ahmadi@yahoo.com ahmadij@sums.ac.ir+98 71 3646 1511

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026